Overcoming resistance in CD44-overexpressing myeloma through combination therapy with ATRA, bortezomib, and NK cells - PubMed
4 hours ago
- #Multiple Myeloma
- #NK Cell Therapy
- #CD44
- CD44 overexpression in multiple myeloma is linked to worse overall survival across disease stages.
- Combining ATRA and bortezomib reduces β-catenin and CD44, inhibits cancer cell growth and spread, and boosts NK cell killing by increasing immune markers.
- In animal models, therapy with NK cells, ATRA, and bortezomib cuts CD44 levels, limits tumor spread, and extends survival without major side effects.
- Clinical data and preclinical results support using ATRA and bortezomib to prime tumors for better NK cell therapy, but more studies in patient models are needed.